Yourgene Health PLC Correction: Director / PDMR Shareholding (6227O)
10 February 2021 - 9:51PM
UK Regulatory
TIDMYGEN
RNS Number : 6227O
Yourgene Health PLC
10 February 2021
The following amendment has been made to the 'Director/PDMR
Shareholding' announcement released on 10 February 2021 at 7.00am
under RNS No 5306O.
The announcement should have stated the percentage holding
following the purchase of shares by Dr John Brown as 0.049% instead
of 0.49% as previously reported.
All other details remain unchanged.
The full amended text is shown below.
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Director / PDMR Shareholding
Manchester, UK - 10 February 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that it was
notified on 9 February 2021 that Dr John Brown, a Director of the
Company, purchased 102,450 Ordinary Shares of 0.10p each at a price
of 12.2 pence per Ordinary Share via a pension fund held in his
name on 9 February 2021.
Following this purchase, Dr John Brown holds 352,450 Ordinary
Shares in the Company which represents 0.049% of the Company's
issued share capital.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr John Brown
----------------------------------- -------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------
a) Position/status Director
----------------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name Yourgene Health plc
----------------------------------- -------------------------------------
b) LEI 213800UUIT8BZE7QEH33
----------------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description of the Ordinary shares of 0.1p each
financial instrument,
type of instrument
Identification code ISIN: GB00BN31ZD89
b) Nature of the transaction Purchase
----------------------------------- -------------------------------------
c) Price(s) and volume(s)
-------------------- ------------
Price(s) Volume(s)
-------------------- ------------
12.2 pence per
share 102,450
------------------------------------------------------------- ------------
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 9 February 2021
----------------------------------- -------------------------------------
f) Place of the transaction UK
----------------------------------- -------------------------------------
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014. The Directors of the
Company take responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEAEAEFLAFEFA
(END) Dow Jones Newswires
February 10, 2021 05:51 ET (10:51 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024